by administrator | Jun 1, 2018 | IMV Inc., News
See original story here HALIFAX, Nova Scotia, May 31, 2018 (GLOBE NEWSWIRE) — IMV Inc. (“IMV” or the “Corporation”) (TSX:IMV) (OTCQX:IMMVD), a clinical stage immunotherapy company, today announced that its common shares have been approved for listing on...
by administrator | Jul 12, 2017 | IMV Inc., News
View original release HALIFAX, Nova Scotia, July 12, 2017 (GLOBE NEWSWIRE) — Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced a significant achievement in its personalized cancer medicines...
by administrator | Apr 18, 2017 | Announcements, IMV Inc., News
Immunovaccine Announces Dosing of First Patient in Investigator-Sponsored Phase 1b/2 Clinical Trial Evaluating Immuno-Oncology Candidate Targeting Incurable HPV-Related Cancers Study Demonstrates Broad Applicability of Immunovaccine’s DepoVax™ Platform for Delivering...
by administrator | Apr 12, 2017 | IMV Inc., News
See original release here 100 Percent of Healthy Older Adult Volunteers Who Responded to Vaccine Achieved a Sustained Antigen-Specific Immune Response that Remains at Peak One Year Post-Vaccination with DPX-RSV; This Level of Response with a Low-dose Volume of a Small...
by administrator | Feb 6, 2017 | Announcements, IMV Inc., News
Original Press Release University Health Network (UHN) in Toronto to Launch Triple-Combination Study Evaluating the Potential for Enhanced Anti-Cancer Activity of Currently Marketed Checkpoint Inhibitor When Combined with DPX-Survivac Halifax, Nova Scotia; February...
by administrator | Sep 23, 2016 | IMV Inc., News
Presentations at RSV16, World Vaccine Congress Europe and IDWeek Conferences Highlight Company’s Progress in Using DepoVax™-based Agents to Address Respiratory Syncytial Virus (RSV) and Life-Threatening Malaria Halifax, Nova Scotia, September 23, 2016 – Immunovaccine...